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Strengths and limitations of this study
 ► This systematic review will use a comprehensive 
search strategy in order to capture all available ev-
idence of economic evaluation studies of cognitive 
behavioural therapy for insomnia (CBT- I).
 ► This review will use standardised tools to extract, 
synthesise and appraise studies in order to provide 
high- level evidence of the value for money of CBT- I.
 ► This review primarily intends to include both full and 
partial economic evaluation studies of CBT- I.
 ► Studies that will be included in the review will be 
limited to English and adult population, which could 
lead to information bias.
AbStrACt
Introduction Insomnia is associated with a number of 
adverse consequences that place a substantial economic 
burden on individuals and society. Cognitive behavioural 
therapy for insomnia (CBT- I) is a promising intervention 
that can improve outcomes in people who suffer from 
insomnia. However, evidence of its cost- effectiveness 
remains unclear. In this study, we will systematically 
review studies that report on economic evaluations of 
CBT- I and investigate the potential economic benefit of 
CBT- I as a treatment for insomnia.
Methods and analysis The search will include studies 
that use full economic evaluation methods (ie, cost- 
effectiveness, cost- utility, cost- benefit, cost- consequences 
and cost- minimisation analysis) and those that apply 
partial economic evaluation approaches (ie, cost 
description, cost- outcome description and cost analysis). 
We will conduct a preliminary search in MEDLINE, Google 
Scholar, MedNar and ProQuest dissertation and theses 
to build the searching terms. A full search strategy using 
all identified keywords and index terms will then be 
undertaken in several databases including MEDLINE, 
Psychinfo, Proquest, Cochrane, Scopus, Cumulative Index 
of Nursing and Allied Health Literature (CINAHL), Web of 
Science and EMBASE. We will adhere to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses for protocol guidelines in this review. Only articles 
in the English language and those reporting on adult 
populations will be included. We will use standardised data 
extraction tools for economic evaluations to retrieve and 
synthesise information from selected studies into themes 
and summarised in a Joanna Briggs Institute dominance 
ranking matrix.
Ethics and dissemination No formal ethics approval 
will be required as we will not be collecting primary 
data. Review findings will be disseminated through 
a peer- reviewed publication, workshops, conference 
presentations and a media release.
PrOSPErO registration number CRD42019133554.
bACkgrOund
Insomnia is characterised by difficulties in 
initiating or maintaining sleep and/or early 
morning awakenings despite sufficient oppor-
tunities for sleep, which results in poor sleep 
quality and daytime impairment.1 Depending 
on the terminology used to define and diag-
nose insomnia, its prevalence can range from 
3.9% to 22.1%, making it one of the most 
common sleep disorders among adults.2–5 
The high prevalence and debilitating nature 
of insomnia contribute to the substantial 
health and economic burden. Insomnia 
is associated with a range of adverse health 
consequences for individuals, including poor 
daytime function and reduced health- related 
quality of life (HRQoL).6 7 Consequently, 
people suffering from insomnia tend to 
have lower work productivity, absenteeism, 
an increased risk of motor vehicle accidents 
and future psychiatric disorders (eg, major 
depressive disorder),8 thereby increasing 
healthcare utilisation and economic costs.7–11
A Canadian study by Daley et al12 estimated 
the total direct and indirect cost of insomnia 
to be Can$6.6 billion per annum or equal to 
1% of the gross domestic product of Quebec 
province. Of this cost, 96% was attributable 
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to indirect costs (presenteeism ($5.0 billion) and absen-
teeism ($970.6 million)), and direct expenditure of 
alcohol use as a sleep aid ($339.8 million). Reynolds 
and Ebben13 estimated that the direct cost of insomnia 
contributes to approximately 4%–16.7% of the total US 
and Canadian national economic cost based on studies 
done in the two countries.12 14 Furthermore, the direct 
cost resulting from hospitalisation, other health services 
utilisation, prescription and over- the counter medicines 
are also substantial.15 Walsh and Engelhardt16 estimated 
the direct cost of insomnia in the USA in 1990 to be 
about US$10.9 billion, of which almost 90% originated 
from nursing home care and 10% was for prescribed 
medications. Reynolds and Ebben13 reanalysed data 
from Stoller14 and reported that the total direct and 
indirect annual expenditure of insomnia in 2016 was 
between US$150.36 and US$174.89 billion after adjusting 
for inflation. In Australia, total health system expendi-
ture attributed to insomnia in 2010 was estimated to be 
$118.7 million, while the indirect financial cost amounted 
to $1.5 billion17. From this earlier estimate, it is evident 
that insomnia is associated with substantial societal 
economic costs as derived by aggregating all direct and 
indirect costs borne by society. Unfortunately, it is diffi-
cult to estimate the true financial cost because most of the 
expenses are made up of indirect costs. The non- uniform 
reporting of insomnia- related expenses between studies 
adds to this difficulty.
In order to reduce the excessive costs of insomnia, it is 
essential to use interventions that can improve symptoms 
and reduce the economic burden. Cognitive behavioural 
therapy for insomnia (CBT- I) is an intervention that aims 
to change dysfunctional thought and behaviour patterns 
through a combination of several components including 
stimulus control, sleep- restriction therapy, cognitive 
therapy for dysfunctional thoughts, sleep hygiene, sleep 
education and relaxation techniques.5 13 18–21 Numerous 
meta- analyses have demonstrated the effectiveness of 
CBT- I in samples with isolated insomnia or insomnia 
co- occurring with specific co- morbidities; in specialist 
care, primary care, and community settings; and with 
different CBT- I modalities including individualised, 
group and online treatments.22–29 CBT- I is usually deliv-
ered over 4–8 weekly sessions; yet its effect in enhancing 
sleep quality and quantity can be sustained for up to 3 
years with minimum risk compared with pharmaco-
therapy.23 30 The sustained improvements in insomnia 
achieved by CBT- I are attributed to the fact that it specif-
ically addresses the key underlying and perpetuating 
dysfunctional behaviours, cognitions and conditioned 
relationships.23 30 Although the effectiveness of CBT- I is 
widely accepted and is recommended as a first- line treat-
ment in the clinical guidelines of several countries,4 31–34 
research that report on its economic benefits is still 
limited.
Economic evaluation is defined as the comparative 
assessment of the cost and benefits of alternative inter-
ventions, or between an assessed intervention and its 
comparator(s).35 The five main types of economic eval-
uation are cost- effectiveness analysis (CEA), cost mini-
misation analysis, cost utility analysis (CUA), cost benefit 
analysis (CBA) and cost consequences analysis (CCA).35 
Despite the abundance of economic evaluation appli-
cations in the healthcare sector, there is a critical gap 
in economic evaluation evidence for CBT- I.36 Previous 
reviews37 38 have acknowledged the lack of studies inves-
tigating economic impact of insomnia interventions and 
argued that treating insomnia costs less than not treating 
the condition. Since then, there have been a growing 
number of economic studies that also incorporate a novel 
delivery mechanism of CBT- I through an online plat-
form.39 We propose to capture the recent and best avail-
able evidence focusing on the application of economic 
evaluation of CBT- I, provide a critical appraisal of such 
evidence and assess the potential economic benefit of this 
intervention in the treatment of insomnia. Importantly, 
no systematic review is currently available that has synthe-
sised this information. Hence, we aim to update existing 
literature in this area by conducting a structured system-
atic review and utilising standard reporting of economic 
studies. Our systematic review and accompanying meta- 
analysis of evidence address this knowledge gap and will 
generate information that will help decision- makers deter-
mine whether implementing CBT- I as first- line insomnia 
treatment provides value for money. Systematic reviews 
that demonstrate the cost- effectiveness of interventions 
help inform policymakers and facilitate the dissemination 
and implementation of effective treatments for insomnia 




The population of interest will be the general adult popu-
lation (individuals aged 18 years or older) who suffer 
from insomnia.
Intervention of interest and comparator
The target intervention is CBT- I. This review will include 
all studies that incorporate at least one of the five most 
widely accepted components of CBT- I, that is, stimulus 
control, sleep restriction, cognitive therapy, sleep hygiene 
and relaxation therapy. Studies of all modalities (eg, 
face- to- face individual/group, telephone, online) will be 
included.
This review will consider studies that compared the 
intervention to control groups. The control groups will 
include individuals who received pharmacotherapy, alter-
native therapies or non- evidence- based treatments to 
treat insomnia or those who receive no treatment.
Context
There will be no restriction as to where the studies took 
place. Studies conducted in primary healthcare, specialist 
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care and online services of high and low resource settings 
will be considered for inclusion in the review.
Costs and outcome measures
This review will report on the estimates of resource use, 
costs, effectiveness and cost- effectiveness of CBT- I in its 
natural units or as per corresponding studies. The find-
ings regarding cost- effectiveness of the intervention 
will be reported in the form of cost per unit of effect 
expressed in clinical outcome units for CEA and CCA 
for example, reduction in insomnia symptom based on a 
specific instrument such as insomnia severity index (ISI) 
scores.40 While for CUA, the findings will be reported as 
cost per a summarised measure of impact on HRQoL 
valued as utility such as cost per quality adjusted life years 
(QALYs) or disability adjusted life years (DALYs). QALYs 
are a combination of life expectancy and the quality of life 
during the survival time which is calculated by multiplying 
utility or HRQoL by survival time while DALYs quantify 
the burden of disease by adding years of life lost due to 
premature mortality and years lived in disability.35 41 The 
findings of CCA, CEA and CUA can be summarised in the 
form of an incremental cost- effectiveness ratio (ICER) 
that is usually the main output or result of economic 
evaluation studies. The ICER is generated by dividing the 
difference in total cost (incremental cost) by the differ-
ence in health outcome (incremental effect) that could 
be QALY, DALY or ISI score relative to study design.35 
Furthermore, this review will report on cost- effectiveness 
acceptability curve (CEAC) for relevant studies that partic-
ularly did not report on the measures outlined earlier. 
The CEAC is a graph that displays the probability that an 
intervention will be the cost- effective option at different 
willingness to pay thresholds. On the other hand, find-
ings from CBA will be in a form of net benefit ratio which 
is a measure, in monetary terms, of the health and non- 
health benefits associated with an intervention relative to 
its costs.35 Assigning a dollar value to health outcomes can 
be achieved in various ways including through the use of 
willingness to pay and human capital approaches.35 In the 
case where CBT- I is integrated with other interventions/
programme (eg, combination of CBT- I and pharmaco-
therapy) and data of reported measures are not available 
separately, the reviewers will analyse measures of interest 
for CBT- I in combination with others.
A societal cost perspective is the broadest viewpoint as 
it accounts for all costs to society as a whole regardless of 
which party bears the cost and is the preferred viewpoint 
for this review.35 Nonetheless, this review will also report 
on other cost perspectives including those of individual 
patient and third- party payers (eg, Ministry of Health, 
public sector, government, national insurance).
Study design
The systematic review will consider partial (eg, cost- 
description studies, cost analysis and cost- outcome 
descriptions) and full economic evaluation studies (CUA, 
CBA, CCA and CEA) that assess CBT- I versus comparators. 
Both model and non- model- based economic evaluations 
will be considered.
Language
Only studies published in English before June 2019.
Exclusion criteria
Studies will be excluded if they report on populations that 
include non- human subjects or children and/or adoles-
cents (<18 years). In addition, the following will also be 
excluded: theory papers, letters, editorials, reviews, theses 
or dissertations and studies where full texts could not be 
obtained.
Search strategy
We will perform the following steps as part of the search 
strategy that aims to find economic evaluation studies 
on CBT- I. First, a preliminary limited search through 
MEDLINE will be undertaken as well as analysis of the 
text words contained in the title and abstract and of the 
index terms used to describe articles. The initial search 
will also include grey literature from ProQuest disserta-
tion and theses and other health data repositories such 
as MedNar and Google Scholar. The first step is crucial 
in order to develop key terms for three key pre- defined 
concepts relating to the research question as follows:
Concept 1 (insomnia, sleep initiation and maintenance 
disorder, sleep wake disorders, sleep disorders, sleep 
problem, sleep complaint, sleep disturbance, poor sleep); 
concept 2 (cognitive behavio* therapy for insomnia, 
CBT- I, bed restriction, relaxation therapy, stimulus 
control, cognitive therapy, biofeedback, sleep hygiene, 
mindfulness therapy, sleep habit therapy, relaxation 
therapy, nonpharma*); concept 3 (economic evaluation, 
economics, QALY, quality of life, value of life, cost and 
cost analysis, cost benefit, cost utility, cost effectiveness, 
healthcare cost, economic model, economic analysis, cost 
minimisation)
Second, we will conduct a full search (see online supple-
mentary appendix 1) using all identified keywords and 
index terms across the following databases: MEDLINE, 
Psychinfo, Proquest, Cochrane, Scopus, Cumulative 
Index of Nursing and Allied Health Literature (CINAHL), 
Web of Science and EMBASE. Concepts 1,2 and 3 will be 
connected by ‘AND’ to run the full search strategy in the 
databases mentioned previously.
Third, relevant titles and abstracts from each data-
base will be screened and two reviewers will select 
eligible studies for full text appraisal. The final step will 
include backward and forward citation- chaining of rele-
vant literature from the reference lists of all identified 
reports and articles. Studies published in English and 
before June 2019 will be considered for inclusion in this 
review.
The schematic presentation of the search strategy using 
the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses for protocol guidelines is presented in 
figure 1.
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Figure 1 A systematic study selection process.
Study selection
Two independent reviewers will assess selected docu-
ments using the inclusion and exclusion criteria before 
including a study in the review. Any disagreement 
that may arise will be resolved through research team 
consensus.
data extraction and synthesis
Data will be extracted from relevant papers included in 
the review using the Joanna Briggs Institute (JBI) Data 
Extraction Form for Economic Evaluations (see online 
supplementary appendix 2).42 The extracted data will 
encompass primarily three sections which include 
descriptive data, results and author conclusions. The 
first section covers description of three sets of items: 
(1) study population, intervention, comparator(s) and 
outcomes; (2) study methods including economic eval-
uation study design type, analytic perspective(s), source 
of effectiveness data, prices and currency used for 
costing, analytical duration/period, sensitivity analysis, 
cost- effectiveness method and measures of resource use, 
cost and health outcome; (3) study setting (geograph-
ical location, healthcare and other service delivery 
setting). This will be followed by the second section that 
reports on the studies’ results for resource usage, cost 
and cost- effectiveness measures. Finally, the authors 
will discuss factors that promote cost- effectiveness of 
the intervention of interest (CBT- I) based on compara-
tive findings of the included studies and other relevant 
economic research.
The nature of data extraction and synthesis will 
depend on the quality, quantity and contexts of the 
identified economic studies. Where possible, economic 
findings (mainly differences in incremental costs 
and outcomes between intervention and comparator 
groups) will be synthesised using meta- analysis in Stata 
V.13.1.43 Binary outcome data will be reported as ORs 
with 95% CI, while mean differences (MD) and 95% CI 
will be reported for continuous data. Estimates of OR 
and MD will be calculated using appropriate stan-
dardised methods (eg, the Mantel- Haenszel44 method 
for binary outcomes and random- effect or fixed- effect 
models45 for continuous data). Heterogeneity will be 
assessed using I2 statistics, with a value of 85% or more 
signifying considerable heterogeneity.46 Healthcare 
costs will be reported in 2019 Australian Dollars after 
conversion and adjustment for inflation where relevant. 
However, if data do not permit for pooling of results, 
qualitative analyses using the JBI dominance ranking 
Matrix,42 which displays three- by- three matrix with three 
classifications (strong dominance, weak dominance and 
non- dominance (online supplementary appendix 3)), 
will be performed.
risk of bias (quality) assessment
Two reviewers will independently assess the methodolog-
ical quality and validity of the relevant economic evalua-
tion studies using the standardised JBI Critical Appraisal 
Checklist for Economic Evaluation47 that is based on the 
guidelines developed by Drummond et al.35 For economic 
evaluation using modelling study design, an additional 
checklist will be utilised based on the critical checklist for 
modelling developed by Philips et al.48 Given the variety 
of settings and type of evaluations of potential included 
studies, the European Network of Health Economic Eval-
uation Databases checklist will be applied to further assess 
transferability and generalisability of the studies to their 
setting of interest.49 The reviewers will individually assess 
each selected study for any risk of bias therein using the 
aforementioned tools.47–49
Ethics and dissemination
No formal ethical approval is required as this study will 
not involve collection of primary data. Findings will be 
disseminated in the following media: publication in peer- 
reviewed journals, presentation at conferences, work-
shops and sharing through a media release.
Patient and public involvement
There is no patient or public involvement in the design or 
planning of this review.
dISCuSSIOn
This systematic review will provide evidence relating 
to economic evaluation of CBT- I across a range of 
settings using a reproducible and transparent proce-
dure for systematic literature searching. This protocol 
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has outlined detailed inclusion and exclusion criteria 
of eligible studies, which include a description of the 
target population, intervention of interest and compar-
ator, context, study design, cost and outcome measures, 
as well as database sources, search strategy, data 
extraction and synthesising method. Using comprehen-
sive and standardised tools to appraise such evidence, 
this study will assess the quality of available studies in 
relation to the resource use, cost and cost- effectiveness 
of CBT- I. Potential limitations of this review include the 
scarcity of evidence and heterogeneity of measures, cost 
perspective and outcomes evaluated which could nega-
tively impact on the transferability and generalisability 
of the data synthesis. Studies that will be included in the 
review will be limited to those reported in the English 
language and in adult populations, which could also 
lead to information bias.
As we are facing resource constraints and rising costs 
in the current healthcare climate, evidence- based guid-
ance regarding cost- effectiveness of CBT- I can poten-
tially help to inform decision making in relation to the 
choice of first- line treatment of insomnia. This review 
will also identify gaps in the evidence base and offer 
recommendations for future research priorities in this 
area.
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